PROGRAM CHAIRS
Neil M. Bressler, MD
James P. Gills Professor of Ophthalmology
Retina Division (Chief: 2005-2018) – Wilmer Eye Institute
Johns Hopkins University School of Medicine & Hospital*
Baltimore, MD
*Participation by Dr. Neil Bressler in this activity does not constitute or imply endorsement by the Johns Hopkins University, the Johns Hopkins Hospital, or the Johns Hopkins Health System nor by JAMA Ophthalmology.
Allen C. Ho, MD, FACS, FASRS
Co-Director, Wills Eye Retina Service and Director,
Retina Research
Wills Eye Hospital
Sidney Kimmel Medical College of Thomas Jefferson University
Philadelphia, PA
PROGRAM OVERVIEW
This interactive, case-based enduring meeting is designed to foster learner collaboration and decision-making for various presentations of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Learn and apply the latest updates in treatment, including novel therapeutic formulations as well as considerations on patient related factors and dosing strategies to individualize care in nAMD and DME.
TARGET AUDIENCE
This activity is designed to meet the educational needs of retina specialists, ophthalmologists, optometrists, pharmacists, and other healthcare providers who manage patients with retinal vascular disease.
LEARNING OBJECTIVES
- Evaluate the burdens of therapy with anti-VEGF modalities in the management of retinal vascular disease, including the frequency of injections
- Summarize established and emerging therapies in DME and nAMD based on patient-specific, treatment-specific, and disease-related factors
- Assess best practices for dosing therapy in patients with DME or nAMD for individual patients
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NURSES (ANCC) CREDIT DESIGNATION
Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
Neil M. Bressler, MD, discloses the following:
| AMA – JAMA Ophthalmology* Editor-in-Chief | Contract from AMA** |
| Bayer Healthcare Pharmaceuticals Inc. | Grant Support to JHU** |
| Biogen | Grant support to JHU** |
| Boehringer Ingelheim | Grant support to JHU** |
| FDA: Chair, Ophthalmic Devices Panel | Honorarium from FDA** |
| Genentech (Roche) | Grant Support to JHU** |
| Jaeb Center for Health Research | Voluntary: Board of Directors |
| Regeneron | Grant Support to JHU** |
| Samsung Bioepis | Grant Support to JHU** |
| EMMES Company, LLC – Chair: Data and Safety Monitoring Committee for The National Eye Institute Intramural Program | Contract from EMMES Company, LLC |
| *Participation by Dr. Neil Bressler in this activity does not constitute or imply endorsement by the Johns Hopkins University, the Johns Hopkins Hospital, or the Johns Hopkins Health System, nor JAMA Ophthalmology | **AMA = American Medical Association; FDA = Food and Drug Administration; JHU = Johns Hopkins University School of Medicine |
Allen C. Ho, MD, discloses the following:
| AcuSurgical, Adverum Biotechnologies, Aerie Pharmaceuticals, Alcon Laboratories, Aldeyra Therapeutics, Allergan, Apellis Pharmaceuticals, Applied Genetic Technologies Corporation (AGTC), Astellas, AsclepiX Therapeutics, Atsena Therapeutics, Beaver-Visitec International, Clearside Biomedical, Dompé, Exegenesis Bio, EyePoint, Eyevensys, Genentech, Gyroscope Technologies, Iveric/Ophthotech, Janssen/Johnson & Johnson, Kiora, Lineage Cell Therapeutics, Nanoscope, Notal Vision, Novartis, Ocugen, Ocular Therapeutics, ONL Therapeutics, Orasis, Oxular, Regeneron Pharmaceuticals, REGENXBIO/AbbVie, and Stealth. | Consultant/Advisor |
| Adverum Biotechnologies, Aerie Pharmaceuticals, Applied Genetic Technologies Corporation (AGTC), Alcon Laboratories, Aldeyra Therapeutics, Allergan, Apellis Pharmaceuticals, AsclepiX Therapeutics, Atsena Therapeutics Genentech, Gyroscope Technologies, Iveric/Ophthotech, Janssen/Johnson & Johnson, Lineage/BioTime, LumiThera, National Eye Institute, Notal Vision, Novartis, ProQR Therapeutics, Regeneron Pharmaceuticals, Inc. and RegenXBio/AbbVie. | Served on the Speakers’ Bureau |
| Covalent Medical, LLC, Gyroscope Technologies, Kiora, and ONL Therapeutics | Ownership |
All relevant financial relationships have been mitigated.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:
- Matthew Frese, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
- Caitlin Rothermel, Medical Director of Med Learning Group, has nothing to disclose.
- Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
- Jessica Feygin, Associate Program Manager of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
- Daniel Dasilva, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg. Physical, Dietary, etc.). Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: November 30, 2023
EXPIRATION DATE: November 30, 2024
Copyright © 2023 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
